Results 81 to 90 of about 14,707,084 (131)

A-Raf [PDF]

open access: yes, 2010
A-Raf (v-raf murine sarcoma 3611 viral oncogene homolog) is a serine/threonine protein kinase of the Raf family that comprises A-Raf, B-Raf and C-Raf.
Kolch, Walter   +3 more
core   +1 more source

Diagnostic Challenge of Contralateral Intranodal Thyroid Inclusions in a Patient With Synchronous Oropharyngeal and Papillary Thyroid Carcinoma: A Case Report

open access: yesClinical Case Reports
Distinguishing benign intranodal thyroid inclusions from metastatic papillary thyroid carcinoma is vital in synchronous malignancies to prevent overstaging.
Bo‐Cheng Rau   +2 more
doaj   +1 more source

Utility of Fine Needle Aspiration Supernatant for Real‐Time PCR–Based Mutation Analysis in Non–Small Cell Lung Cancer

open access: yesDiagnostic Cytopathology, Volume 54, Issue 11, Page 805-811, November 2026.
ABSTRACT Background The emergence of personalized therapy and molecular sequencing has significantly transformed the management of advanced non–small cell lung carcinoma (NSCLC). Supernatants obtained from fine needle aspiration (FNA) have been shown to be a reliable source of high‐quality nucleic acid for molecular testing.
Adeyinka Akinsanya   +9 more
wiley   +1 more source

Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Management

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This comprehensive review summarizes gastric cancer epidemiology, multifactorial risk factors (like infectious, dietary, genetic), pathogenesis such as precancerous evolution, molecular alterations, and a focus on the bidirectional interactions between gastric cancer cells and macrophages in the tumor microenvironment.
Yixuan Xin   +6 more
wiley   +1 more source

[B-raf gene encodes for multiple isoforms with Mek-1 kinase activity].

open access: yes, 1995
International audienceThe c-Rmil/B-raf proto-oncogene belongs to the mil/raf family encoding serine/threonine protein kinases shown to be involved in signal transduction from the membrane to the nucleus.
Eychène, Alain   +3 more
core  

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

open access: yesThe Journal of Pathology, Volume 270, Issue 3, Page 380-395, November 2026.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti   +21 more
wiley   +1 more source

Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines.

open access: yes, 1995
International audienceThe B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases. It encodes multiple protein isoforms previously shown to be expressed predominantly in neural tissues.
Eychène, Alain   +6 more
core  

G48A, a new KRAS mutation found in lung adenocarcinoma

open access: yes, 2016
A new somatic mutation in the coding region of Kirsten rat sarcoma viral oncogene homolog gene (KRAS), G48A, has been identified in a patient with non-small cell lung cancer (NSCLC).
Garassino, Marina C.   +7 more
core   +1 more source

B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222.

open access: yes, 1995
International audienceThe B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases. It encodes multiple protein isoforms resulting from alternative splicing of two exons located upstream of the kinase domain.
Eychène, Alain   +6 more
core   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

open access: yesCancer Science, Volume 117, Issue 11, Page 2901-2909, November 2026.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy